country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-161331

Copy Link Print Information

S16–1029

S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 11.35 nM and 48.1 nM for eqBChE and hBChE, respectively. S16–1029 could cross the blood-brain barrier (BBB) and reach the central nervous system (CNS). S16–1029 can be used for Alzheimer's disease (AD) research.

For research use only. We do not sell to patients.

CAS No.: 2653349-51-8
Formula: C₂₃H₂₅N₇O₃
Molecular Weight:447.49

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (282 KB)

S16–1029 Chemical Structure

CAS No.: 2653349-51-8

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]

eqBCHE

11.35 nM (IC₅₀)

hBCHE

48.1 nM (IC₅₀)

All Cholinesterase (ChE) Isoforms :

AChE
BChE

Cellular Effect

Cell Line	Type	Value	Description	References
SH-SY5Y	IC₅₀	89.77 μM Compound: S16-1029	Cytotoxicity against human SH-SY5Y cells assessed as survival rate incubated for 24 hrs by MTT assay Cytotoxicity against human SH-SY5Y cells assessed as survival rate incubated for 24 hrs by MTT assay	[PMID: 38452730]

Chemical Information

CAS No. 2653349-51-8
Molecular Weight 447.49
Formula C₂₃H₂₅N₇O₃
SMILES

O=C(CN1C(C2=NON=C2N)=NC3=C1C=CC=C3)NC4=CC=C(CCN5CCOCC5)C=C4
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocols

All Animals and Diseases

Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Shuaishuai Xing, et al. Optimizing drug-like properties of selective butyrylcholinesterase inhibitors for cognitive improvement: Enhancing aqueous solubility by disrupting molecular plane. Eur J Med Chem. 2024 Mar 2:268:116289. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote